{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":4,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03735121\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["subcutaneous atezolizumab"]],"indication":"previously treated locally advanced or metastatic NSCLC","name":"IMscin001","nct_id":"NCT03735121","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imscin001-nct03735121. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Atezolizumab","label":"Atezolizumab (Part 2)","type":"EXPERIMENTAL"},{"description":"Atezolizumab+recombinant human hyaluronidase (rHuPH20), followed by Atezolizumab","label":"Cohort 1: Atezolizumab+rHuPH20 (Part 1)","type":"EXPERIMENTAL"},{"description":"Atezolizumab+rHuPH20, followed by Atezolizumab","label":"Cohort 2: Atezolizumab+rHuPH20 (Part 1)","type":"EXPERIMENTAL"},{"description":"Atezolizumab+rHuPH20, followed by Atezolizumab","label":"Cohort 3: Atezolizumab+rHuPH20(Part 1)","type":"EXPERIMENTAL"},{"description":"Atezolizumab + rHuPH20","label":"Atezolizumab + rHuPH20 (Part 2)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-11-11","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":438,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"rHuPH20","otherNames":["ENHANZE"],"type":"DRUG"}],"last_update":"2025-12-05","lead_sponsor":"Hoffmann-La Roche","official_title":"A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-04-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1","timeFrame":"Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)"},{"measure":"Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1","timeFrame":"Predose on Day 1 of Cycle 2 (Cycle length =21 days)"},{"measure":"Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1","timeFrame":"From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)"}],"references":[{"citation":"Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Felip E, Majem M, Korbenfeld E, Kolb-Sielecki J, Isla D, Barata T, Bustillos A, Herraez-Baranda LA, Tosti N, Young F, Zanghi J, Cappuzzo F. Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. Lung Cancer. 2026 Jul;217:109452. doi: 10.1016/j.lungcan.2026.109452. Epub 2026 May 12.","pmid":"42214243","type":"DERIVED"},{"citation":"Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda LA, Shearer-Kang E, Liu X, Tosti N, Williams P, Castro Sanchez AY, Zanghi J, Felip E. Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC. J Thorac Oncol. 2024 Oct;19(10):1460-1466. doi: 10.1016/j.jtho.2024.05.005. Epub 2024 May 9.","pmid":"38729426","type":"DERIVED"},{"citation":"Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, Chan P, Shearer-Kang E, Liu X, Tosti N, Zanghi JA, Leutgeb B, Felip E. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023 Aug;34(8):693-702. doi: 10.1016/j.annonc.2023.05.009. Epub 2023 Jun 1.","pmid":"37268157","type":"DERIVED"},{"citation":"Felip E, Burotto M, Zvirbule Z, Herraez-Baranda LA, Chanu P, Kshirsagar S, Maiya V, Chan P, Pozzi E, Marchand M, Monchalin M, Tanaka K, Tosti N, Wang B, Restuccia E. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1142-1155. doi: 10.1002/cpdd.936. Epub 2021 Mar 31.","pmid":"33788415","type":"DERIVED"}],"start_date":{"date":"2018-12-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03735121"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imscin001-nct03735121"}